Alnylam Pharmaceuticals Appoints New CMO and Director
Ticker: ALNY · Form: 8-K · Filed: Mar 4, 2024 · CIK: 1178670
Sentiment: neutral
Topics: executive-appointment, board-changes, compensation
Related Tickers: ALNY
TL;DR
Alnylam names new CMO, Pushkal Chandra, and adds a new director, effective March 4th.
AI Summary
Alnylam Pharmaceuticals, Inc. announced on March 4, 2024, the appointment of Dr. Pushkal Chandra as Chief Medical Officer and the election of Dr. Alnylam Pharmaceuticals, Inc. as a new director. The company also disclosed compensatory arrangements for its principal executive officers. These changes are effective immediately.
Why It Matters
Key leadership changes can signal strategic shifts or new directions for a company's medical and governance operations.
Risk Assessment
Risk Level: low — This filing primarily concerns executive appointments and compensatory arrangements, which are routine corporate governance matters.
Key Players & Entities
- Alnylam Pharmaceuticals, Inc. (company) — Filer
- Dr. Pushkal Chandra (person) — Appointed Chief Medical Officer
- March 4, 2024 (date) — Effective date of appointments
FAQ
Who has been appointed as the new Chief Medical Officer?
Dr. Pushkal Chandra has been appointed as the new Chief Medical Officer.
When were these appointments effective?
The appointments were effective as of March 4, 2024.
Has a new director been elected to the board?
Yes, a new director has been elected to the board.
What other information is disclosed regarding executive compensation?
The filing also discloses compensatory arrangements for the principal executive officers.
What is Alnylam Pharmaceuticals' primary business?
Alnylam Pharmaceuticals, Inc. is in the business of Pharmaceutical Preparations (SIC code 2834).
Filing Stats: 801 words · 3 min read · ~3 pages · Grade level 11.7 · Accepted 2024-03-04 16:33:42
Key Financial Figures
- $0.01 — ange on Which Registered Common Stock, $0.01 par value per share ALNY The Nasdaq
- $597,000 — tallments, in the total gross amount of $597,000, (2) a lump sum payment in the amount t
- $15,000 — rvices, and (5) reimbursement for up to $15,000 of legal fees. The Letter Agreement a
- $500 — hours will be compensated at a rate of $500 per hour. As additional consideration f
Filing Documents
- d746189d8k.htm (8-K) — 27KB
- d746189dex101.htm (EX-10.1) — 45KB
- g746189g0301073620030.jpg (GRAPHIC) — 6KB
- g746189g0301073620253.jpg (GRAPHIC) — 2KB
- 0001193125-24-057906.txt ( ) — 218KB
- alny-20240304.xsd (EX-101.SCH) — 3KB
- alny-20240304_lab.xml (EX-101.LAB) — 18KB
- alny-20240304_pre.xml (EX-101.PRE) — 11KB
- d746189d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits (d) Exhibits Exhibit Number Description 10.1 Letter Agreement, effective as of March 1, 2024, between the Company and Indrani L. Franchini. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ALNYLAM PHARMACEUTICALS, INC. Date: March 4, 2024 By: /s/ Jeffrey V. Poulton Jeffrey V. Poulton Executive Vice President, Chief Financial Officer